PHARMACOLOGICAL USE OF NEOLIGNANS, THEIR DERIVATIVES AND ANALOGS, COMPOSITION AND OBTAINING PROCESS FOR THE TREATMENT OF DISEASES CAUSED BY ATYPIC MYCOBACTERIA AND MYCOBACTERIA
Universidade de São Paulo - USP;Universidade Estadual de Campinas - UNICAMP
发明人:
Ana Olívia de Souza,Célio Lopes Silva,Lauro Euclides Soares Barata,Maria Vitória Lopes Badra Bentley,Paulo Roberto Regazi Minarini
申请号：
BRPI0600679
公开号：
BRPI0600679B1
申请日:
2006.02.23
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
Pharmacological use of neolignans, their derivatives and analogues, composition and process for obtaining them in the treatment of diseases caused by atypical microbacteria and atypical microbes The present invention describes the potential use of neolignan class compounds in both human and animal health in treatment of already established infections and diseases (human tuberculosis, bovine tuberculosis, leprosy and microbacteriosis, in addition to cases in which microbacteria act opportunistically, such as acquired immunodeficiency syndrome - hiv), caused by atypical microbacteria and dust. therefore applicable in the pharmaceutical sector. More specifically, the present invention relates without limitation to the use of polymeric micro or nanoparticles of lactic and glycolic acids (d, l-plga) containing neolignans and / or their derivatives and synthetic analogs obtained as for example by the art. Modified emulsification and solvent evaporation as a modified drug release system for the treatment of infectious diseases such as tuberculosis and tuberculosis associated with other diseases. The formulations are stable and suitable for human or animal use and may be administered by different routes such as orally, nasal, subcutaneous, intradermal, intramuscular or may be combined with other formulations.uso farmacológico de neolignanas, seus derivados e análogos, composição e seu processo de obtenção no tratamento de doenças causadas por microbactérias e microbactérias atípicas a presente invenção descreve o potencial uso de compostos da classe de neolignanas na área da saúde, tanto humana como animal, no tratamento de infecções e doenças já estabelecidas (tuberculose humana, tuberculose bovina, hanseníase e microbacterioses, além os casos em que as microbactérias atuam de forma oportunista, como por exemplo na síndrome da imunodeficiência adquirida - hiv), causadas pó microbactérias e microbactérias atípicas, sendo, portanto, aplicável no setor farmacêutico. mais espe
